331 related articles for article (PubMed ID: 30909510)
1. Therapeutic Targeting of Collective Invasion in Ovarian Cancer.
Moffitt L; Karimnia N; Stephens A; Bilandzic M
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909510
[TBL] [Abstract][Full Text] [Related]
2. Cancer stem-like cells with hybrid epithelial/mesenchymal phenotype leading the collective invasion.
Quan Q; Wang X; Lu C; Ma W; Wang Y; Xia G; Wang C; Yang G
Cancer Sci; 2020 Feb; 111(2):467-476. PubMed ID: 31845453
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism.
Liao J; Qian F; Tchabo N; Mhawech-Fauceglia P; Beck A; Qian Z; Wang X; Huss WJ; Lele SB; Morrison CD; Odunsi K
PLoS One; 2014; 9(1):e84941. PubMed ID: 24409314
[TBL] [Abstract][Full Text] [Related]
4. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach.
Tomao F; Papa A; Rossi L; Strudel M; Vici P; Lo Russo G; Tomao S
J Exp Clin Cancer Res; 2013 Aug; 32(1):48. PubMed ID: 23902592
[TBL] [Abstract][Full Text] [Related]
5. Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.
Klymenko Y; Kim O; Loughran E; Yang J; Lombard R; Alber M; Stack MS
Oncogene; 2017 Oct; 36(42):5840-5851. PubMed ID: 28628116
[TBL] [Abstract][Full Text] [Related]
6. Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance.
Ahmed N; Abubaker K; Findlay J; Quinn M
J Cell Biochem; 2013 Jan; 114(1):21-34. PubMed ID: 22887554
[TBL] [Abstract][Full Text] [Related]
7. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
[TBL] [Abstract][Full Text] [Related]
8. ZEB2 facilitates peritoneal metastasis by regulating the invasiveness and tumorigenesis of cancer stem-like cells in high-grade serous ovarian cancers.
Li Y; Fei H; Lin Q; Liang F; You Y; Li M; Wu M; Qu Y; Li P; Yuan Y; Chen T; Jiang H
Oncogene; 2021 Aug; 40(32):5131-5141. PubMed ID: 34211089
[TBL] [Abstract][Full Text] [Related]
9. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids.
He M; Wang D; Zou D; Wang C; Lopes-Bastos B; Jiang WG; Chester J; Zhou Q; Cai J
Oncotarget; 2016 Dec; 7(52):86374-86387. PubMed ID: 27863439
[TBL] [Abstract][Full Text] [Related]
10. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
11. Targeting ovarian cancer-initiating cells.
Murphy SK
Anticancer Agents Med Chem; 2010 Feb; 10(2):157-63. PubMed ID: 20184540
[TBL] [Abstract][Full Text] [Related]
12. The Transcoelomic Ecosystem and Epithelial Ovarian Cancer Dissemination.
Ritch SJ; Telleria CM
Front Endocrinol (Lausanne); 2022; 13():886533. PubMed ID: 35574025
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer stem cell: A potential therapeutic target for overcoming multidrug resistance.
Mihanfar A; Aghazadeh Attari J; Mohebbi I; Majidinia M; Kaviani M; Yousefi M; Yousefi B
J Cell Physiol; 2019 Apr; 234(4):3238-3253. PubMed ID: 30317560
[TBL] [Abstract][Full Text] [Related]
14. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
Glackin CA
Enzymes; 2018; 44():83-101. PubMed ID: 30360816
[TBL] [Abstract][Full Text] [Related]
16. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness.
Muñoz-Galván S; Felipe-Abrio B; Verdugo-Sivianes EM; Perez M; Jiménez-García MP; Suarez-Martinez E; Estevez-Garcia P; Carnero A
Mol Cancer; 2020 Jan; 19(1):7. PubMed ID: 31926547
[TBL] [Abstract][Full Text] [Related]
18. Eliminating ovarian cancer stem cells: a potential therapeutic target for ovarian cancer chemoresistance.
Wang X; Li X; Fu X; Bai M; Li X; Mei Q; Nie J; Wu Z; Han W
Curr Protein Pept Sci; 2015; 16(4):270-8. PubMed ID: 25929861
[TBL] [Abstract][Full Text] [Related]
19. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
20. CD44 variant 6 is correlated with peritoneal dissemination and poor prognosis in patients with advanced epithelial ovarian cancer.
Tjhay F; Motohara T; Tayama S; Narantuya D; Fujimoto K; Guo J; Sakaguchi I; Honda R; Tashiro H; Katabuchi H
Cancer Sci; 2015 Oct; 106(10):1421-8. PubMed ID: 26250934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
